Intestinal microbiome and permeability in patients with autoimmune hepatitis

Best Practice and Research: Clinical Gastroenterology

Volumn 31, Issue 6, 2017, Pages 669-673

  Cai, Wangfeng ^a   Ran, Ying ^a   Li, Yanni ^a   Wang, Bangmao ^a   Zhou, Lu ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Autoimmune hepatitis; Microbiome; Molecular mimicry; Permeability

Indexed keywords

CORTICOSTEROID; HLA DR3 ANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; AUTOIMMUNE HEPATITIS; CROSS REACTION; ENVIRONMENTAL FACTOR; GENETIC PREDISPOSITION; GERMFREE MOUSE; HUMAN; IMMUNOPATHOGENESIS; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; MOLECULAR MIMICRY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; REVIEW; TRANSGENIC MOUSE; ANIMAL; IMMUNOLOGY; PATHOLOGY;

ANIMALS; GASTROINTESTINAL MICROBIOME; HEPATITIS, AUTOIMMUNE; HUMANS;

EID: 85030026787     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2017.09.013     Document Type: Review

References (63)

1. Zeuzem, S., Gut-liver axis. Int J Colorectal Dis 15:2 (2000), 59–82.
2. EASL Clinical Practice Guidelines, Autoimmune hepatitis. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 63:4 (2015), 971–1004.
3. Yuksel, M., Wang, Y., Tai, N., Peng, J., Guo, J., Beland, K., et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology 62:5 (2015), 1536–1550.
4. Lin, R., Zhou, L., Zhang, J., Wang, B., Abnormal intestinal permeability and microbiota in patients with autoimmune hepatitis. Int J Clin Exp Pathol 8:5 (2015), 5153–5160.
5. Wei, Y., Zeng, B., Chen, J., Cui, G., Lu, C., Wu, W., et al. Enterogenous bacterial glycolipids are required for the generation of natural killer T cells mediated liver injury. Sci Rep, 6, 2016, 36365.
6. Levy, M., Kolodziejczyk, A.A., Thaiss, C.A., Elinav, E., Dysbiosis and the immune system. Nat Rev Immunol 17:4 (2017), 219–232.
7. Campbell, A.W., The gut, intestinal permeability, and autoimmunity. Altern Ther Health Med 21:1 (2015), 6–7.
8. Hevia, A., Milani, C., Lopez, P., Cuervo, A., Arboleya, S., Duranti, S., et al. Intestinal dysbiosis associated with systemic lupus erythematosus. Mbio 5:5 (2014), 1514–1548.
9. He, Z., Shao, T., Li, H., Xie, Z., Wen, C., Alterations of the gut microbiome in Chinese patients with systemic lupus erythematosus. Gut Pathog, 8(1), 2016, 64.
10. Fox, R.I., Sjogren's syndrome. Controversies and progress. Clin Lab Med 17:3 (1997), 431–444.
11. De Paiva, C.S., Jones, D.B., Stern, M.E., Bian, F., Moore, Q.L., Corbiere, S., et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep, 6(1), 2016, 23561.
12. Knip, M., Siljander, H., The role of the intestinal microbiota in type 1 diabetes mellitus. Nat Rev Endocrinol 12:3 (2016), 154–167.
13. Sargent, J., Autoimmunity: T1DM and the gut microbiome. Nat Rev Endocrinol, 11(4), 2015, 193.
14. Wang, S.J., Kao, C.H., Chen, D.U., Lan, J.L., Intestinal permeability test in systemic lupus erythematosus. Zhonghua Yi Xue Za Zhi (Taipei) 49:1 (1992), 29–33.
15. Fresko, I., Hamuryudan, V., Demir, M., Hizli, N., Sayman, H., Melikoglu, M., et al. Intestinal permeability in Behcet's syndrome. Ann Rheum Dis 60:1 (2001), 65–66.
16. Li, N., Hatch, M., Wasserfall, C.H., Douglas-Escobar, M., Atkinson, M.A., Schatz, D.A., et al. Butyrate and type 1 diabetes mellitus: can we fix the intestinal leak?. J Pediatr Gastroenterol Nutr 51:4 (2010), 414–417.
17. Li, X., Atkinson, M.A., The role for gut permeability in the pathogenesis of type 1 diabetes – a solid or leaky concept?. Pediatr Diabetes 16:7 (2015), 485–492.
18. Bosi, E., Molteni, L., Radaelli, M.G., Folini, L., Fermo, I., Bazzigaluppi, E., et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49:12 (2006), 2824–2827.
19. Visser, J., Rozing, J., Sapone, A., Lammers, K., Fasano, A., Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N. Y Acad Sci 1165 (2009), 195–205.
20. Terjung, B., Sohne, J., Lechtenberg, B., Gottwein, J., Muennich, M., Herzog, V., et al. p-ANCAs in autoimmune liver disorders recognise human-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59:6 (2010), 808–816.
21. Terjung, B., Spengler, U., Atypical p-ANCA in PSC and AIH: a hint toward a ”leaky gut. Clin Rev Aller Immunol 36:1 (2009), 40–51.
22. Bogdanos, D., Baum, H., Okamoto, M., Mont alto, P., Sharma, U.C., Rigopoulou, E.I., et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 42:2 (2005), 458–465.
23. Berg, C.P., Kannan, T.R., Klein, R., Gregor, M., Baseman, J.B., Wesselborg, S., et al. Mycoplasma antigens as a possible trigger for the induction of antimitochondrial antibodies in primary biliary cirrhosis. Liver Int 29:6 (2009), 797–809.
24. Kerkar, N., Choudhuri, K., Ma, Y., Mahmoud, A., Bogdanos, D.P., Muratori, L., et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol 170:3 (2003), 1481–1489.
25. Kammer, A.R., van der Burg, S.H., Grabscheid, B., Hunziker, I.P., Kwappenberg, K.M., Reichen, J., et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med 190:2 (1999), 169–176.
26. Al-Hamoudi, W.K., Severe autoimmune hepatitis triggered by varicella zoster infection. World J Gastroenterol 15:8 (2009), 1004–1006.
27. Ulluwishewa, D., Anderson, R.C., Young, W., McNabb, W.C., van Baarlen, P., Moughan, P.J., et al. Live Faecalibacterium prausnitzii in an apical anaerobic model of the intestinal epithelial barrier. Cell Microbiol 17:2 (2015), 226–240.
28. Chen, J., Zhang, Y., Xiao, G., A preliminary study of the postburn intestinal biological barrier injury in severely burned rats. Zhonghua Shao Shang Za Zhi 18:4 (2002), 216–219.
29. Wang, H., Gong, J., Wang, W., Long, Y., Fu, X., Fu, Y., et al. Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model?. PLoS One, 9(3), 2014, 90153.
30. Mokkala, K., Laitinen, K., Roytio, H., Bifidobacterium lactis 420 and fish oil enhance intestinal epithelial integrity in Caco-2 cells. Nutr Res 36:3 (2016), 246–252.
31. Arseneault-Breard, J., Rondeau, I., Gilbert, K., Girard, S.A., Tompkins, T.A., Godbout, R., et al. Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. Br J Nutr 107:12 (2012), 1793–1799.
32. Persborn, M., Gerritsen, J., Wallon, C., Carlsson, A., Akkermans, L.M.A., Söderholm, J.D., The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharm Ther 38:7 (2013), 772–783.
33. Yang, K.M., Jiang, Z.Y., Zheng, C.T., Wang, L., Yang, X.F., Effect of Lactobacillus plantarum on diarrhea and intestinal barrier function of young piglets challenged with enterotoxigenic Escherichia coli K88. J Anim Sci 92:4 (2014), 1496–1503.
34. Li, M., Zhu, L., Xie, A., Yuan, J., Oral administration of Saccharomyces boulardii ameliorates carbon tetrachloride-induced liver fibrosis in rats via reducing intestinal permeability and modulating gut microbial composition. Inflammation 38:1 (2015), 170–179.
35. Kwak, Y.K., Vikstrom, E., Magnusson, K.E., Vecsey-Semjen, B., Colque-Navarro, P., Mollby, R., The Staphylococcus aureus alpha-toxin perturbs the barrier function in Caco-2 epithelial cell monolayers by altering junctional integrity. Infect Immun 80:5 (2012), 1670–1680.
36. Almeida, J.A., Ponnuraj, N.P., Lee, J.J., Utterback, P., Gaskins, H.R., Dilger, R.N., et al. Effects of dietary clays on performance and intestinal mucus barrier of broiler chicks challenged with Salmonella enterica serovar Typhimurium and on goblet cell function in vitro. Poult Sci 93:4 (2014), 839–847.
37. Deitch, E.A., Berg, R.D., Endotoxin but not malnutrition promotes bacterial translocation of the gut flora in burned mice. J Trauma 27:2 (1987), 161–166.
38. Bjarnason, I., Peters, T.J., Wise, R.J., The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1:8370 (1984), 179–182.
39. Engen, P.A., Green, S.J., Voigt, R.M., Forsyth, C.B., Keshavarzian, A., The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res 37:2 (2015), 223–236.
40. Hartmann, P., Seebauer, C.T., Schnabl, B., Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res 39:5 (2015), 763–775.
41. Papp, M., Norman, G.L., Vitalis, Z., Tornai, I., Altorjay, I., Foldi, I., et al. Presence of anti-microbial antibodies in liver cirrhosis – a tell-tale sign of compromised immunity?. PLoS One, 5(9), 2010, 12957.
42. Kim, B.I., Kim, H.J., Park, J.H., Park, D.I., Cho, Y.K., Sohn, C.I., et al. Increased intestinal permeability as a predictor of bacterial infections in patients with decompensated liver cirrhosis and hemorrhage. J Gastroenterol Hepatol 26:3 (2011), 550–557.
43. Cao, X., Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol 16:1 (2016), 35–50.
44. Suresh, R., Mosser, D.M., Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ 37:4 (2013), 284–291.
45. Lawless, M.W., Greene, C.M., Toll-like receptor signalling in liver disease: ER stress the missing link?. Cytokine 59:2 (2012), 195–202.
46. Li, M., Zhou, Y., Feng, G., Su, S.B., The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases. Curr Mol Med 9:3 (2009), 365–374.
47. Lang, K.S., Georgiev, P., Recher, M., Navarini, A.A., Bergthaler, A., Heikenwalder, M., et al. Immuno privileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 116:9 (2006), 2456–2463.
48. Limmer, A., Sacher, T., Alferink, J., Kretschmar, M., Schonrich, G., Nichterlein, T., et al. Failure to induce organ-specific autoimmunity by breaking of tolerance: importance of the microenvironment. Eur J Immunol 28:8 (1998), 2395–2406.
49. Chen, J., Wei, Y., He, J., Cui, G., Zhu, Y., Lu, C., et al. Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. Sci Rep, 4, 2014, 7259.
50. Margalit, M., Abu, G.S., Alper, R., Elinav, E., Klein, A., Doviner, V., et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 289:5 (2005), 917–925.
51. Liberal, R., Grant, C.R., Mieli-Vergani, G., Vergani, D., Autoimmune hepatitis: a comprehensive review. J Autoimmun 41 (2013), 126–139.
52. Umemura, T., Ota, M., Genetic factors affect the etiology, clinical characteristics and outcome of autoimmune hepatitis. Clin J Gastroenterol 8:6 (2015), 360–366.
53. De Boer, Y.S., van Gerven, N.M., Zwiers, A., Verwer, B.J., van Hoek, B., van Erpecum, K.J., et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology0 147:2 (2014), 443–452.
54. Kubinak, J.L., Stephens, W.Z., Soto, R., Petersen, C., Chiaro, T., Gogokhia, L., et al. MHC variation sculpts individualized microbial communities that control susceptibility to enteric infection. Nat Commun, 6, 2015, 8642.
55. Llopis, M., Cassard, A.M., Wrzosek, L., Boschat, L., Bruneau, A., Ferrere, G., et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut 65:5 (2016), 830–839.
56. David, L.A., Maurice, C.F., Carmody, R.N., Gootenberg, D.B., Button, J.E., Wolfe, B.E., et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:7484 (2014), 559–563.
57. Grasa, L., Abecia, L., Forcen, R., Castro, M., de Jalon, J.A., Latorre, E., et al. Antibiotic-induced depletion of murine microbiota induces mild inflammation and changes in toll-like receptor patterns and intestinal motility. Microb Ecol 70:3 (2015), 835–848.
58. Czaja, A.J., Diagnosis and management of autoimmune hepatitis. Clin Liver Dis 19:1 (2015), 57–79.
59. Kim, H.B., Wang, Y., Sun, X., A detrimental role of immunosuppressive drug, dexamethasone, during Clostridium difficile infection in association with a gastrointestinal microbial shift. J Microbiol Biotechnol 26:3 (2016), 567–571.
60. Huang, E.Y., Inoue, T., Leone, V.A., Dalal, S., Touw, K., Wang, Y., et al. Using corticosteroids to reshape the gut microbiome: implications for inflammatory bowel diseases. Inflamm Bowel Dis 21:5 (2015), 963–972.
61. Wild, G.E., Waschke, K.A., Bitton, A., Thomson, A.B., The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 18:3 (2003), 309–317.
62. Scaldaferri, F., Pizzoferrato, M., Gerardi, V., Lopetuso, L., Gasbarrini, A., The gut barrier: new acquisitions and therapeutic approaches. J Clin Gastroenterol 46 (2012), 12–17.
63. Tourret, J., Willing, B.P., Dion, S., MacPherson, J., Denamur, E., Finlay, B.B., Immunosuppressive treatment alters secretion of ileal antimicrobial peptides and gut microbiota, and favors subsequent colonization by uropathogenic Escherichia coli. Transplantation 101:1 (2017), 74–82.